Enzymotec Ltd. (ENZY) Downgraded by Wells Fargo & Co. to “Market Perform”
Enzymotec Ltd. (NASDAQ:ENZY) was downgraded by investment analysts at Wells Fargo & Co. from an “outperform” rating to a “market perform” rating in a report issued on Thursday.
ENZY has been the topic of a number of other reports. Zacks Investment Research raised shares of Enzymotec from a “sell” rating to a “hold” rating in a research note on Tuesday, October 11th. Jefferies Group reaffirmed a “hold” rating on shares of Enzymotec in a research note on Thursday, August 4th.
Enzymotec (NASDAQ:ENZY) opened at 5.50 on Thursday. Enzymotec has a 52 week low of $5.20 and a 52 week high of $10.32. The company has a 50-day moving average of $6.87 and a 200-day moving average of $7.78. The firm has a market cap of $124.95 million, a price-to-earnings ratio of 28.95 and a beta of 1.26.
Enzymotec (NASDAQ:ENZY) last released its quarterly earnings data on Wednesday, November 16th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by $0.04. Enzymotec had a net margin of 8.37% and a return on equity of 3.12%. The business earned $11.40 million during the quarter, compared to the consensus estimate of $13.29 million. During the same period last year, the business posted $0.08 earnings per share. The firm’s quarterly revenue was down 8.1% on a year-over-year basis. Equities research analysts forecast that Enzymotec will post $0.27 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ENZY. Van ECK Associates Corp raised its position in Enzymotec by 5.9% in the second quarter. Van ECK Associates Corp now owns 12,659 shares of the company’s stock worth $106,000 after buying an additional 706 shares during the last quarter. Geode Capital Management LLC purchased a new position in Enzymotec during the first quarter worth $114,000. TFS Capital LLC purchased a new position in Enzymotec during the second quarter worth $153,000. State of New Jersey Common Pension Fund D raised its position in Enzymotec by 13.5% in the third quarter. State of New Jersey Common Pension Fund D now owns 24,997 shares of the company’s stock worth $175,000 after buying an additional 2,976 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. raised its position in Enzymotec by 12.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 21,313 shares of the company’s stock worth $178,000 after buying an additional 2,298 shares during the last quarter. 36.19% of the stock is currently owned by institutional investors.
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Receive News & Stock Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related stocks with our FREE daily email newsletter.